Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, announced the closing of an oversubscribed $125 million Series B financing co-led by Sanofi Ventures and Janus Henderson Investors, with participation from both existing and new investors. New investors include Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P. and Woodline Partners LP. Existing investors include Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capital, Biovision Ventures and Checkpoint Capital. Paulina Hill, Ph.D., Partner at Sanofi Ventures, will join Diagonal's Board of Directors in conjunction with the financing.